Grant: Engage Grants Program
University of Toronto
$25,000.00
Development of microfluidic angiogenesis assay for drug testing and companion diagnostics
FY 2016-17
Summary
Armour Therapeutics Inc. is a biopharmaceutical company based in Toronto, Ontario that has developed a candidate drug for advanced prostate cancer (PCa), the most common type of cancer among men in Canada and in the developed world. The candidate drug, AT-001, offers the potential for patients to continue hormone therapy even beyond the point where tumours become insensitive to traditional anti-hormone therapies. While Armour Therapeutics has made progress to bring AT-001 to the clinic, key questions related to the effects of AT-001 on blood vessel growth, or angiogenesis, remain unanswered. Furthermore, drug regulatory bodies are increasingly favouring the development of complementary diagnostic tests, termed companion diagnostic(CDx) assays, that help determine which patients will respond most effectively to the drug (i.e, the vision of personalized medicine). The global market for CDx assays is growing, and is expected to reach ~$10 billion by 2020. To assist Armour Therapeutics with the development of AT-001 and its clinical translation, the proposed project aims to develop a microfluidic cell culture angiogenesis assay, for use by Armour Therapeutics, to further elucidate the effects of AT-001 on angiogenesis within a prostate cancer tissue model. The assay will also be assessed for potential application as a CDx assay paired with AT-001 for advanced prostate cancertherapy. Developing a CDx tool in concert with AT-001 will establish Armour Therapeutics as an innovative leader in the pharmaceutical industry, and will further promote the Ontario region and Canada as global leaders in biotechnology research and innovation.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
500666-2016
Name nom
Young, EdmondWaiKeung
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Development of microfluidic angiogenesis assay for drug testing and companion diagnostics
Keyword
NSERC
Application summary
Armour Therapeutics Inc. is a biopharmaceutical company based in Toronto, Ontario that has developed a candidate drug for advanced prostate cancer (PCa), the most common type of cancer among men in Canada and in the developed world. The candidate drug, AT-001, offers the potential for patients to continue hormone therapy even beyond the point where tumours become insensitive to traditional anti-hormone therapies. While Armour Therapeutics has made progress to bring AT-001 to the clinic, key questions related to the effects of AT-001 on blood vessel growth, or angiogenesis, remain unanswered. Furthermore, drug regulatory bodies are increasingly favouring the development of complementary diagnostic tests, termed companion diagnostic(CDx) assays, that help determine which patients will respond most effectively to the drug (i.e, the vision of personalized medicine). The global market for CDx assays is growing, and is expected to reach ~$10 billion by 2020. To assist Armour Therapeutics with the development of AT-001 and its clinical translation, the proposed project aims to develop a microfluidic cell culture angiogenesis assay, for use by Armour Therapeutics, to further elucidate the effects of AT-001 on angiogenesis within a prostate cancer tissue model. The assay will also be assessed for potential application as a CDx assay paired with AT-001 for advanced prostate cancertherapy. Developing a CDx tool in concert with AT-001 will establish Armour Therapeutics as an innovative leader in the pharmaceutical industry, and will further promote the Ontario region and Canada as global leaders in biotechnology research and innovation.